Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | USP5 | P45974 | 1/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942270 | 0.84 | DPP4 (0.49) | ALDH1A1USP5TSHRSMN1; SMN2TP53 | |
| SCHEMBL1103991 | 0.84 | ESR2 (0.52) | ALDH1A1CYP2C19MAPTNPY5RSYK | |
| SCHEMBL942579 | 0.84 | TP53 (0.56) | ALDH1A1USP5SLC18A3LMNATP53 | |
| SCHEMBL14321122 | 0.84 | SLC18A3 (0.46) | HTTALDH1A1CYP2C19SLC18A3LMNA | |
| SCHEMBL15574503 | 0.84 | USP5 (0.47) | HTTUSP5LMNAMAPTNPY5R | |
| SCHEMBL16994785 | 0.84 | USP5 (0.47) | HTTALDH1A1USP5SLC18A3TSHR | |
| SCHEMBL16994786 | 0.84 | LMNA (0.56) | HTTALDH1A1USP5SLC18A3SMN1; SMN2 | |
| SCHEMBL9320214 | 0.84 | NPY5R (0.58) | HTTALDH1A1USP5SLC18A3TSHR | |
| SCHEMBL16994754 | 0.81 | CYP2C19 (0.46) | HTTALDH1A1CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL1103992 | 0.81 | HTT (0.57) | HTTALDH1A1CYP2C19USP5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20220119429-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| WO-2020210377-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2758398-B1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL]-2-AZABICYCLO [2.2.1]HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-9274419-B2 | Blue photosensitive resin composition for color filter and application thereof | CHI MEI CORPORATION (TW) | 2016-03-01 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
| US-20150268554-A1 | BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF | CHI MEI CORPORATION (TW) | 2015-09-24 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1828160-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067114-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284387-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, API5 | HTT 1912/4885ALDH1A1 1518/4885CYP2C19 4465/4885 |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | HTT 666/4885ALDH1A1 2642/4885CYP2C19 3244/4885 |
| US-20220119429-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | FLI1, FOLR2, FOLR1 | HTT 4268/4885ALDH1A1 1304/4885CYP2C19 382/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | HTT 1328/4885ALDH1A1 780/4885CYP2C19 253/4885 |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | HTT 2265/4885ALDH1A1 2059/4885CYP2C19 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.